Recent advances in machine learning and experimental biology have offered breakthrough
solutions to problems such as protein structure prediction that were long thought to be …

Immunotherapy is a major breakthrough in the treatment of cancer in recent years. Immune
checkpoint inhibitors (ICIs) including programmed death-ligand 1 (PD-L1)/programmed …

NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021 in: Journal of the
National Comprehensive Cancer Network Volume 19 Issue 3 (2021) Jump to Content User …

In cancer, evolutionary forces select for clones that evade the immune system. Here we
analyzed> 10,000 primary tumors and 356 immune-checkpoint-treated metastases using …

Background: Non-melanoma skin cancer (NMSC) stands as an umbrella term for common
cutaneous malignancies, including basal cell carcinoma (BCC) and cutaneous squamous …

Triple negative breast cancer (TNBC) is a high-risk and aggressive malignancy
characterized by the absence of estrogen receptors (ER) and progesterone receptors (PR) …

Simple Summary Immunotherapy stands as a cornerstone in the treatment of advanced lung
cancer patients without an oncogenic driver mutation. This comprehensive review provides …

Simple Summary Immunotherapy leads to highly variable responses in lung cancer patients.
We assessed the value of a blood-based test to predict which patients would benefit from …

Simple Summary The introduction of immunotherapy modified the cancer treatment
landscape, especially for non-small cell lung cancer (NSCLC). Unfortunately, only a …

Immune checkpoint inhibitors (ICIs) are highly concerned in the treatment of non-small cell
lung cancer (NSCLC), represented by inhibitors of programmed death protein 1 (PD-1) and …